Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer.

about

Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer.

Item

http://www.wikidata.org/entity/Q55322511

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Cancer Treatment-Induced Bone ...... and Men With Prostate Cancer.

@en

Cancer Treatment-Induced Bone ...... and Men With Prostate Cancer.

@nl

type

Item

label

Cancer Treatment-Induced Bone ...... and Men With Prostate Cancer.

@en

Cancer Treatment-Induced Bone ...... and Men With Prostate Cancer.

@nl

prefLabel

Cancer Treatment-Induced Bone ...... and Men With Prostate Cancer.

@en

Cancer Treatment-Induced Bone ...... and Men With Prostate Cancer.

@nl

P1476

Cancer Treatment-Induced Bone ...... and Men With Prostate Cancer.

@en

P2093

Catherine Van Poznak

http://www.w3.org/2001/XMLSchema#string

Erika Faircloth

http://www.w3.org/2001/XMLSchema#string

Pamela Taxel

http://www.w3.org/2001/XMLSchema#string

Sana Idrees

http://www.w3.org/2001/XMLSchema#string

P2860

Bone health in adults treated with endocrine therapy for early breast or prostate cancer

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.

Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women: results from the Women's Health Initiative.

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

Degarelix.

P304

574-588

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JS.2018-00052

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29942922

http://www.w3.org/2001/XMLSchema#string

P932

6007245

http://www.w3.org/2001/XMLSchema#string